Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros

Base de datos
Tipo del documento
Intervalo de año de publicación
1.
JAMA Netw Open ; 5(11): e2242378, 2022 11 01.
Artículo en Inglés | MEDLINE | ID: mdl-36383379

RESUMEN

Importance: Bladder-preserving trimodality therapy can be an effective alternative to radical cystectomy for treatment of muscle-invasive bladder cancer (MIBC), but biomarkers are needed to guide optimal patient selection. The DNA repair protein MRE11 is a candidate response biomarker that has not been validated in prospective cohorts using standardized measurement approaches. Objective: To evaluate MRE11 expression as a prognostic biomarker in MIBC patients receiving trimodality therapy using automated quantitative image analysis. Design, Setting, and Participants: This prognostic study analyzed patients with MIBC pooled from 6 prospective phase I/II, II, or III trials of trimodality therapy (Radiation Therapy Oncology Group [RTOG] 8802, 8903, 9506, 9706, 9906, and 0233) across 37 participating institutions in North America from 1988 to 2007. Eligible patients had nonmetastatic MIBC and were enrolled in 1 of the 6 trimodality therapy clinical trials. Analyses were completed August 2020. Exposures: Trimodality therapy with transurethral bladder tumor resection and cisplatin-based chemoradiation therapy. Main Outcomes and Measures: MRE11 expression and association with disease-specific (bladder cancer) mortality (DSM), defined as death from bladder cancer. Pretreatment tumor tissues were processed for immunofluorescence with anti-MRE11 antibody and analyzed using automated quantitative image analysis to calculate a normalized score for MRE11 based on nuclear-to-cytoplasmic (NC) signal ratio. Results: Of 465 patients from 6 trials, 168 patients had available tissue, of which 135 were analyzable for MRE11 expression (median age of 65 years [minimum-maximum, 34-90 years]; 111 [82.2%] men). Median (minimum-maximum) follow-up for alive patients was 5.0 (0.6-11.7) years. Median (Q1-Q3) MRE11 NC signal ratio was 2.41 (1.49-3.34). Patients with an MRE11 NC ratio above 1.49 (ie, above first quartile) had a significantly lower DSM (HR, 0.50; 95% CI, 0.26-0.93; P = .03). The 4-year DSM was 41.0% (95% CI, 23.2%-58.0%) for patients with an MRE11 NC signal ratio of 1.49 or lower vs 21.0% (95% CI, 13.4%-29.8%) for a ratio above 1.49. MRE11 NC signal ratio was not significantly associated with overall survival (HR, 0.84; 95% CI, 0.49-1.44). Conclusions and Relevance: Higher MRE11 NC signal ratios were associated with better DSM after trimodality therapy. Lower MRE11 NC signal ratios identified a poor prognosis subgroup that may benefit from intensification of therapy.


Asunto(s)
Neoplasias de la Vejiga Urinaria , Masculino , Adulto , Humanos , Anciano , Femenino , Neoplasias de la Vejiga Urinaria/tratamiento farmacológico , Estudios Prospectivos , Invasividad Neoplásica , Resultado del Tratamiento , Biomarcadores , Músculos/patología
2.
Plast Reconstr Surg ; 143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma): 7S-14S, 2019 03.
Artículo en Inglés | MEDLINE | ID: mdl-30817551

RESUMEN

The first case of breast implant-associated anaplastic large cell lymphoma (breast implant ALCL) was described by John Keech and the late Brevator Creech in 1997. In the following 2 decades, much research has led to acceptance of breast implant ALCL as a specific clinicopathologic entity, a process that we bring up to life through the memories of 6 persons who were involved in this progress, although we acknowledge that many others also have contributed to the current state of the art of this disease. Dr. Keech recalls the events that led him and Creech to first report the disease. Ahmet Dogan and colleagues at the Mayo Clinic described a series of 4 patients with breast implant ALCL, and led to increased awareness of breast implant ALCL in the pathology community. Daphne de Jong and colleagues in the Netherlands were the first to provide epidemiologic evidence to support the association between breast implants and ALCL. Garry Brody was one of the first investigators to collect a large number of patients with the disease, present the spectrum of clinical findings, and alert the community of plastic surgeons. Roberto Miranda and L. Jeffrey Medeiros and colleagues studied the pathologic findings of a large number of cases of breast implant ALCL, and published the findings in 2 impactful studies in the medical oncology literature. The recognition and acceptance of this disease by surgeons, epidemiologists, and medical oncologists, working together, has led to subsequent studies on the pathogenesis and optimal therapy of this disease.


Asunto(s)
Implantes de Mama/efectos adversos , Implantes de Mama/historia , Neoplasias de la Mama/etiología , Linfoma Anaplásico de Células Grandes/etiología , Linfoma Anaplásico de Células Grandes/historia , Adulto , Implantación de Mama/efectos adversos , Implantación de Mama/historia , Implantación de Mama/métodos , Neoplasias de la Mama/historia , Femenino , Salud Global , Historia del Siglo XX , Historia del Siglo XXI , Humanos , Rol del Médico
3.
J Clin Oncol ; 32(2): 114-20, 2014 Jan 10.
Artículo en Inglés | MEDLINE | ID: mdl-24323027

RESUMEN

PURPOSE: Breast implant-associated anaplastic large-cell lymphoma (ALCL) is a recently described clinicopathologic entity that usually presents as an effusion-associated fibrous capsule surrounding an implant. Less frequently, it presents as a mass. The natural history of this disease and long-term outcomes are unknown. PATIENTS AND METHODS: We reviewed the literature for all published cases of breast implant-associated ALCL from 1997 to December 2012 and contacted corresponding authors to update clinical follow-up. RESULTS: The median overall survival (OS) for 60 patients was 12 years (median follow-up, 2 years; range, 0-14 years). Capsulectomy and implant removal was performed on 56 of 60 patients (93%). Therapeutic data were available for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who did not receive chemotherapy, 12 patients opted for watchful waiting and four patients received radiation therapy alone. Thirty-nine (93%) of 42 patients with disease confined by the fibrous capsule achieved complete remission, compared with complete remission in 13 (72%) of 18 patients with a tumor mass. Patients with a breast mass had worse OS and progression-free survival (PFS; P = .052 and P = .03, respectively). The OS or PFS were similar between patients who received and did not receive chemotherapy (P = .44 and P = .28, respectively). CONCLUSION: Most patients with breast implant-associated ALCL who had disease confined within the fibrous capsule achieved complete remission. Proper management for these patients may be limited to capsulectomy and implant removal. Patients who present with a mass have a more aggressive clinical course that may be fatal, justifying cytotoxic chemotherapy in addition to removal of implants.


Asunto(s)
Implantes de Mama/efectos adversos , Neoplasias de la Mama/etiología , Linfoma Anaplásico de Células Grandes/etiología , Adulto , Anciano , Anciano de 80 o más Años , Mama/efectos de los fármacos , Mama/patología , Mama/cirugía , Neoplasias de la Mama/diagnóstico , Neoplasias de la Mama/terapia , Remoción de Dispositivos/estadística & datos numéricos , Supervivencia sin Enfermedad , Quimioterapia/métodos , Quimioterapia/estadística & datos numéricos , Femenino , Estudios de Seguimiento , Humanos , Linfoma Anaplásico de Células Grandes/diagnóstico , Linfoma Anaplásico de Células Grandes/terapia , Persona de Mediana Edad , Factores de Tiempo , Espera Vigilante/estadística & datos numéricos
4.
J Oncol Pract ; 6(5): 263-4, 2010 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21197193

RESUMEN

Evolution is brought about by subtle environmental pressures over time or by a cataclysmic extinction event. The latter is the case for the solo medical oncologist, with the event being the Medicare Modernization Act of 2003.

5.
J Oncol Pract ; 1(2): 52-3, 2005 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-20871679
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA